Paul Fitzgerald, The Australian National University, papregistry@anu.edu.au
The purpose of the AIPPAP Research Registry is the collection of outcome and safety data on the use of novel interventional pharmacotherapy approaches, including ketamine treatment and psychedelic-assisted psychotherapy for mental health disorders. The AIPPAP Research Registry will include any patients receiving MDMA, psilocybin, or ketamine who are referred by their treating physician and consent to participate in data collection. The outcomes measured will depend on their diagnosis.
- Registry website
- Peer-reviewed publications
- With the participants consent, clinical outcome data can be reported to their treating doctor/team via an automated system
Various PROMS to measure changes in depression, post traumatic stress disorder, obsessive-compulsive disorder , and other psychiatric symptoms, including:
- Patient Health Questionnaire-9 (PHQ-9);
- Impact of Event Scale-Revised (IES-R) (PTSD only);
- Obsessional Compulsive Inventory - Revised (OCI-R) (OCD only);
- Generalize Anxiety Disorder 7 - Item (GAD-7);
- Depression Anxiety and Stress Scale 21 (DASS-21);
- The Stanford Expectations of Treatment Scale (SETS);
- Ten Item Personality Inventory (TIPI);
- Side Effects;
- Assessment of Quality of Life (AQoL-8D);
- Psychological Insight Questionnaire (PIQ);
- Revised Mystical Experience Questionnaire (MEQ30);
- Multidimensional Health Locus of Control (MHLC);
- Collaborative Assessment and Management of Suicidality (CAMS);
- Self-efficacy to Manage Chronic Disease (SEMCD)
Nil
No sites. Registry works by referral by treating physician/team.